MARKET

BCRX

BCRX

BioCryst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.500
-0.270
-7.16%
After Hours: 3.530 +0.03 +0.86% 16:09 09/23 EDT
OPEN
3.750
PREV CLOSE
3.770
HIGH
3.800
LOW
3.480
VOLUME
4.87M
TURNOVER
--
52 WEEK HIGH
6.29
52 WEEK LOW
1.380
MARKET CAP
617.98M
P/E (TTM)
-4.1504
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Does BioCryst Pharmaceuticals (NASDAQ:BCRX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Simply Wall St. · 1d ago
BioCryst to Present at 22nd Annual H.C. Wainwright Global Investment Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 22nd annual H.C. Wainwright Global Investment Conference on Monday, September 14, 2020 at 9:30 a.m. ET. The conference is being conducted
GlobeNewswire · 09/08 11:00
U.S. Government to purchase additional RAPIVAB from Biocryst for ~$7M
U.S. Department of Health and Human Services has exercised its option to purchase an additional 10,000 doses of BioCryst’s (BCRX) approved antiviral influenza therapy, RAPIVAB (peramivir injection), for ~$7M to deliver
Seekingalpha · 09/03 12:24
U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst’s approved antiviral influenza therapy,
GlobeNewswire · 09/03 12:00
NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir
RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst a new contract (75N93020C00055) totaling
GlobeNewswire · 08/31 14:29
BioCryst Pharmaceuticals up 12% premarket on orphan drug tag for BCX9930
BioCryst Pharmaceuticals (BCRX) +5% as U.S.FDA approves orphan drug designation for its oral Factor D inhibitor, BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria. Additionally, FDA has also granted fast
Seekingalpha · 08/31 12:00
FDA Grants Orphan Drug Designation for BCX9930 in PNH
RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for its oral Factor D inhibitor, BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria
GlobeNewswire · 08/31 12:00
BioCryst Pharmaceuticals' (NASDAQ:BCRX) Shareholders Are Down 62% On Their Shares
Simply Wall St. · 08/17 16:41
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCRX. Analyze the recent business situations of BioCryst Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BCRX stock price target is 8.50 with a high estimate of 13.00 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 226
Institutional Holdings: 140.29M
% Owned: 79.46%
Shares Outstanding: 176.57M
TypeInstitutionsShares
Increased
55
31.24M
New
68
-5.88M
Decreased
38
15.23M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.27%
Pharmaceuticals & Medical Research
-1.30%
Key Executives
Chairman/Independent Director
Robert Ingram
Chief Executive Officer/President/Director
Jon Stonehouse
Chief Financial Officer/Senior Vice President
Anthony Doyle
Senior Vice President/Secretary
Alane Barnes
Senior Vice President
Yarlagadda Babu
Senior Vice President
Charles Gayer
Senior Vice President
William Sheridan
Senior Vice President
Megan Sniecinski
Director
Sanj Patel
Chief Accounting Officer
Michael Jones
Vice President/General Manager
Allen Hodge
Independent Director
George Abercrombie
Independent Director
Stephen Aselage
Independent Director
Theresa Heggie
Independent Director
Nancy Hutson
Independent Director
Kenneth Lee
Independent Director
Alan Levin
Independent Director
Helen Thackray
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of BioCryst Pharmaceuticals, Inc. stock information, including NASDAQ:BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.